FDA gains oversight of compounding pharmacies; patients get safety labels.
S. 3794 — SAFE Drugs Act of 2026 · Filed by Jim Banks (R-IN) · 1 cosponsor · Introduced Feb 5, 2026 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires compounding pharmacies and physicians who send compounded drugs across state lines to report serious adverse events to the FDA and relevant states, and to file annual reports if they send more than 5% of their output interstate. It also mandates that compounded drugs carry labels stating they are not FDA-approved and include adverse-event reporting contact information. The bill tightens federal oversight of an industry that currently operates under lighter regulation than mass-manufactured pharmaceuticals.
Why we flagged it
The bill's operative mechanism is mandatory adverse-event reporting and labeling for compounded drugs sent across state lines. This is a regulatory tightening, not a deregulation or carve-out. It expands FDA and state oversight of an industry segment that previously had minimal federal reporting requirements.
What the text implies
- Compounding pharmacies and physicians may face increased compliance costs (systems for tracking, reporting, labeling), which could be passed to patients or reduce the economic viability of small compounding operations.
- The bill creates a federal-state information-sharing system, centralizing data on compounded-drug distribution; this may enable future enforcement actions or restrictions based on adverse-event patterns.
- Hospital-based compounding is explicitly exempted, creating a regulatory gap: hospital pharmacies can compound and dispense without the same reporting burden, potentially creating a two-tier system.
- The bill does not establish penalties or enforcement mechanisms for non-compliance; effectiveness depends on FDA and state follow-through and appropriations.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Ordinary citizens gain transparency and safety oversight: they learn when compounded drugs cause harm, can report problems directly, and receive clear labeling that a drug is not FDA-approved. The reporting and labeling requirements create accountability for an industry that has historically operated with minimal federal visibility, reducing the risk of harm from unmonitored compounded products.
Who stands to gain
- FDA (expanded oversight authority and data collection)
- State pharmacy boards (expanded reporting and enforcement authority)
- Pharmaceutical manufacturers (potential competitive advantage if compounding becomes more costly or
Named in the bill
FDA, State pharmacy boards, Licensed pharmacists, Licensed physicians, Compounding pharmacies, Outsourcing facilities, Hospital pharmacies, Federal Food, Drug, and Cosmetic Act, Section 503A
Where it stands
1 cosponsor: 1 Democrats.
- Feb 5, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Feb 5, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
- Jul 22, 2026 — Reported out of committee · Congress.gov: “Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
9 lobbying clients named this bill on 9 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $600,000 in lobbying spend. A filing names 3 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 89% of bills with at least one filing.
Jim Banks, the sponsor, reported $559,626 in PAC receipts in the 2026 cycle. $2,500 of that came from 1 PAC tied to these lobbying clients.
- Professional Compounding Centers of America — $220,000 on 1 filing
- Alliance for Safe Online Pharmacies (asop Global) — $60,000 on 1 filing
- Novo Nordisk Inc. — $60,000 on 1 filing
- Alliance for Pharmacy Compounding — $50,000 on 1 filing
- Eli Lilly & Company — $50,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (3,680 characters) on Aug 16, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“FDA gains oversight of compounding pharmacies; patients get safety labels.” QuorumCivic. https://share.quorumcivic.app/bill/119/s3794 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.